rs2278236 — ANGPTL4 ANGPTL4 Intronic Variant

Intronic ANGPTL4 variant tagging reduced LPL inhibition; the A allele is associated with higher HDL cholesterol and lower cardiovascular event risk

Strong Protective Share

Details

Gene: ANGPTL4
Chromosome: 19
Risk allele: A
Clinical: Protective
Evidence: Strong

Population Frequency

26%

50%

24%

External

SNPedia ClinVar dbSNP

See your personal result for ANGPTL4

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ANGPTL4 — Your Triglyceride Brake and HDL Regulator

Your body has a master switch that controls how much fat gets pulled out of your bloodstream after a meal. That switch is ANGPTL4¹¹ ANGPTL4
Angiopoietin-like protein 4 — a secreted protein that acts as a context-sensitive brake on fat-clearing enzymes, and this variant in its gene is linked to how effectively it operates. People with the A allele at rs2278236 tend to carry higher HDL cholesterol and face a measurably lower risk of cardiovascular events.

The Mechanism

ANGPTL4 works by inhibiting lipoprotein lipase (LPL)²² lipoprotein lipase (LPL)
LPL is the enzyme that breaks down triglycerides in VLDL and chylomicrons, releasing fatty acids for uptake into muscle and adipose tissue. When ANGPTL4 is highly active, it clamps down on LPL, meaning triglycerides accumulate in the blood rather than being cleared efficiently. When ANGPTL4 activity is lower — as appears to be tagged by the A allele at rs2278236 — LPL can work more freely, clearing triglycerides from circulation and generating HDL particles as a byproduct of that lipolytic process.

The variant sits within an intron of ANGPTL4 and does not change the protein sequence directly. It is most likely a regulatory tag — either altering expression levels or in linkage disequilibrium with a functional variant elsewhere in the gene that modulates ANGPTL4 output.

The Evidence

A prospective cohort study of 983 coronary patients³³ 983 coronary patients
Muendlein et al. Angiopoietin-like protein 4 significantly predicts future cardiovascular events in coronary patients. Atherosclerosis, 2014 found that rs2278236 significantly predicted future cardiovascular events independently of conventional risk factors. Carrying the A allele was associated with a 24% lower event rate (adjusted HR 0.76, 95% CI 0.61–0.94, p=0.012). Plasma ANGPTL4 levels were higher in patients with metabolic syndrome (26.0 vs 22.2 ng/ml, p=0.008), supporting the connection between ANGPTL4 activity and cardiometabolic risk.

GWAS data in the EBI GWAS Catalog show rs2278236-A is associated with increased HDL cholesterol at genome-wide significance (p=1×10⁻¹⁶) and also with increased phosphatidylcholine, total cholines, and phosphoglycerides in lipoprotein particles (p=2×10⁻¹⁸ to 3×10⁻¹⁷), consistent with a shift toward a more favorable lipoprotein particle profile.

Diet-gene interaction is also documented: a randomized controlled trial⁴⁴ randomized controlled trial
Hannon et al. SNPs Related to Lipoprotein Metabolism Are Associated with Blood Lipid Changes following Regular Avocado Intake. J Nutr, 2020 of 115 adults found that ANGPTL4 rs2278236 genotype modified total cholesterol responses to regular avocado intake (interaction p=0.02), suggesting the variant shapes how dietary fat quality translates into lipid outcomes.

Notably, a study in 629 white adults at risk for type 2 diabetes found no association⁵⁵ found no association
Staiger et al. Genetic variation within ANGPTL4 is not associated with metabolic traits. Metabolism, 2008 between rs2278236 and fasting triglycerides, insulin sensitivity, or BMI in cross-sectional analysis, suggesting the variant's benefit may be more apparent under metabolic challenge (high dietary fat load, cardiovascular disease context) than at rest.

Practical Actions

For GG carriers — the group with lowest HDL-raising allele count — the actionable lever is dietary fat quality and omega-3 intake. Because ANGPTL4 activity is sensitive to fatty acid composition, shifting from saturated fats (which upregulate ANGPTL4) to unsaturated fats and EPA/DHA can partly compensate for less favorable ANGPTL4 regulation. Routine fasting lipid panels including HDL, triglycerides, and non-HDL cholesterol will track whether these changes are working.

AA carriers still benefit from similar strategies but start from a more favorable HDL baseline.

Interactions

ANGPTL4 operates within a three-protein system alongside ANGPTL3 and ANGPTL8 that coordinates tissue-specific LPL regulation. The variant rs4076317 (another ANGPTL4 tag SNP) has been studied in the same coronary patient cohort and may compound lipid effects. ANGPTL3 variants (e.g., rs2131925) represent a related LPL-inhibition pathway; combined ANGPTL3 + ANGPTL4 effects on triglycerides may be additive.

Nutrient Interactions

dietary fat altered_metabolism

omega-3 fatty acids altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant:

GG “Baseline HDL” Normal

Standard ANGPTL4 activity — no HDL-raising advantage

The GG genotype reflects the GRCh38 reference state at this locus. Large GWAS studies (EBI GWAS Catalog) consistently show that the A allele — not present in GG individuals — is associated with higher HDL at genome-wide significance (p=1×10⁻¹⁶). GG carriers lack this advantage, meaning dietary and lifestyle inputs have relatively more influence over their HDL trajectory. The Muendlein 2014 cohort found G allele dosage was associated with higher cardiovascular event rates, though effect sizes were modest at the individual level (HR per allele ~1.15). Monitoring HDL and triglycerides periodically allows early detection of an adverse lipid trend before it becomes clinically significant.

AG “Moderate HDL Advantage” Beneficial

One HDL-raising A allele — moderately favorable lipid profile

The AG genotype represents heterozygous carriage of the HDL-associated intronic A variant. GWAS data show the A allele is associated with increased HDL (beta ~0.033 SD units per allele) and with higher phosphatidylcholine and phosphoglyceride content of lipoprotein particles — a pattern consistent with improved lipoprotein quality alongside quantity. The diet-gene interaction documented in the Hannon 2020 RCT (p=0.02 interaction with avocado intake) suggests that dietary fat quality shapes how strongly this variant expresses its phenotype. High saturated fat intake may blunt the benefit by upregulating ANGPTL4 expression through PPAR-mediated pathways.

AA “Highest HDL Advantage” Beneficial

Two copies of the HDL-raising A allele — most favorable ANGPTL4 profile

Homozygous AA carriers carry the maximum dose of the intronic A variant associated with reduced ANGPTL4-mediated LPL inhibition. Beyond HDL, GWAS data also show AA-associated increases in phosphatidylcholine (p=9×10⁻²⁰) and total cholines in lipoprotein particles — markers of lipoprotein quality that are associated with reduced cardiovascular risk. The Hannon 2020 diet-gene interaction study found that regular avocado intake interacted with ANGPTL4 rs2278236 genotype on total cholesterol (p=0.02), suggesting that dietary fat quality modulates how fully this genetic advantage is realized. Saturated fat can upregulate ANGPTL4 via PPARδ activation, potentially dampening the genetically favorable LPL activity; monounsaturated and omega-3 fats work with the variant rather than against it.